JDRF Statement on Centers for Medicare & Medicaid Services Announcement of Affordable Insulin Options for Medicare Beneficiaries

For people with type 1 diabetes (T1D), insulin is a lifesaving drug that no one should ever have to ration or go without. JDRF has long advocated for affordable insulin, urging manufacturers, health plans, employers, and policymakers to ensure that people with T1D can obtain the lifesaving medication they need at low and predictable out-of-pocket costs.   

JDRF welcomes the May 26 announcement by the Centers for Medicare & Medicaid Services (CMS) about more affordable insulin options for people in the Medicare program. The new program is an important step forward. At JDRF, we will continue to urgently advocate for long-term solutions that make this lifesaving drug affordable for all, whether someone has Medicare, another kind of insurance, or no insurance at all.  

JDRF offers information about currently available resources to help people access and pay for insulin and other prescriptions at jdrf.org/costs. For information and resources on how to manage T1D during the COVID-19 pandemic, visit jdrf.org/coronavirus.